Jul. 14 at 5:15 PM
eXoZymes (Nasdaq:
$EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point.
eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1
"It is fundamentally different from GLP-1 drugs," Perryman said. "GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat."
From the same segment:
• NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom
• In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population
• The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway
Watch the full webinar: https://youtu.be/OmH3TaaMT20
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
$DNLI,
$TWST,
$DNA,
$ARKG